Intragastric Balloons Market Size, Share, Growth, and Industry Analysis, By Types (Single function, Multifunction), By Applications (Vacuum, Wipe, Mop ) , and Regional Insights and Forecast to 2034

Intragastric Balloons Market Size

The Global Intragastric Balloons Market size was USD 31 Million in 2024 and is projected to reach USD 34.16 Million in 2025, USD 37.65 Million in 2026, and USD 81.88 Million by 2034, expanding at a steady rate of 10.2% during the forecast period (2025–2034). The market is witnessing accelerated demand due to increasing obesity rates worldwide, rising awareness of minimally invasive bariatric procedures, and continuous innovation in balloon-based weight-loss technologies. More than 42% of obese adults globally are turning to non-surgical treatments, positioning this market as a rapidly evolving healthcare segment.

In the United States, the Intragastric Balloons Market continues to dominate with strong growth prospects, contributing approximately 33% to the global market. Around 38% of adults in the U.S. are classified as obese, creating high procedural demand. Over 65% of bariatric clinics in the country now offer intragastric balloon procedures, while patient satisfaction levels surpass 72% post-treatment. The growing shift toward outpatient and endoscopic balloon placements underscores the expanding adoption of this therapy across North America’s healthcare system.

Key Findings

• Market Size: Global Intragastric Balloons Market reached USD 31 Million in 2024, USD 34.16 Million in 2025, and is expected to hit USD 81.88 Million by 2034, growing steadily at 10.2% across the forecast period.
• Growth Drivers: Over 42% of obese adults seek non-surgical solutions, 31% of hospitals expand bariatric departments, and 29% of patients prefer adjustable balloon technologies.
• Trends: Around 73% of procedures use saline-filled balloons, 72% are endoscopic-based, and 26% involve next-gen swallowable capsules with remote deflation capabilities.
• Key Players: Ecovacs, IRobot, LG, Samsung, Philips & more.
• Regional Insights: North America holds around 38% of the global market driven by high obesity awareness and strong healthcare infrastructure. Europe follows with 29% supported by advanced clinical facilities. Asia-Pacific captures 23% led by rising obesity rates and urbanization, while the Middle East & Africa account for 10% with growing bariatric adoption.
• Challenges: About 8% of patients face mild complications, 20% struggle with compliance, and 15% of clinics report limited reimbursement access affecting adoption rates.
• Industry Impact: Over 40% of healthcare facilities have integrated intragastric balloon systems, while 33% report improved long-term obesity management outcomes.
• Recent Developments: Nearly 36% of companies launched biocompatible materials, 24% introduced smart balloon systems, and 18% partnered for AI-based treatment monitoring.

The Intragastric Balloons Market is transforming global obesity treatment by offering a safer, faster, and less invasive alternative to surgical interventions. Around 70% of global hospitals have integrated balloon therapies into their weight management programs. Technological innovations, such as adjustable-volume balloons and wireless tracking systems, are improving safety and patient comfort. With increasing medical tourism in Asia-Pacific and over 50% of clinics in developed regions now offering balloon-based treatments, this market stands at the forefront of next-generation bariatric care.

Intragastric Balloons Market Trends

The Intragastric Balloons Market is witnessing substantial growth due to rising global obesity rates and the increasing preference for non-surgical weight-loss procedures. Around 39% of the global adult population is classified as overweight, and approximately 13% are obese, which is driving the need for effective bariatric interventions. More than 65% of patients undergoing obesity management prefer minimally invasive treatments like intragastric balloons over traditional bariatric surgery. North America dominates the market with nearly 38% share, followed by Europe at 29%, Asia-Pacific at 23%, and the Middle East & Africa holding 10%. Gas-filled balloon systems have captured almost 27% of new installations due to improved comfort and reduced post-procedure complications. Approximately 72% of procedures are conducted using endoscopic insertion techniques, reflecting their widespread adoption in clinical settings. Meanwhile, adjustable balloons account for 33% of total market use, indicating strong patient preference for customizable solutions. Moreover, nearly 46% of hospitals globally have introduced intragastric balloon procedures, supported by technological advancements, increased awareness, and cost-effective device availability.

Intragastric Balloons Market Dynamics

OPPORTUNITY

Rising Obesity Rates in Emerging Economies

Emerging economies represent a massive opportunity for the intragastric balloons market. Over 39% of the adult population in regions such as North America and 29% in Europe are classified as overweight, while obesity in Asia-Pacific is increasing at more than 18% annually. Latin America contributes nearly 6% to the total global market share, driven by urban lifestyle shifts and dietary changes. As awareness of minimally invasive weight-loss options rises, more than 25% of healthcare providers in Asia-Pacific have begun offering intragastric balloon (IGB) therapies. This widening adoption base highlights strong potential in developing regions with growing middle-class populations and rising healthcare spending.

DRIVERS

Growing Demand for Non-Surgical Weight Loss Procedures

The shift toward non-surgical and minimally invasive weight-loss solutions is a key driver of the intragastric balloons market. Around 72% of all IGB procedures are performed using endoscopic techniques, offering safer and faster recovery options compared to traditional bariatric surgeries. Over 65% of patients prefer temporary, reversible weight-loss treatments, making IGBs increasingly attractive. Additionally, the saline-filled balloon category holds a commanding 73% share due to its clinical safety profile and wide acceptance. This patient preference and technological reliability continue to strengthen the adoption of intragastric balloon procedures globally.

RESTRAINTS

"Limited Reimbursement and Cost Barriers"

Limited reimbursement coverage remains a significant restraint, particularly in low- and middle-income regions. While North America captures over 38% of the global intragastric balloons market due to robust insurance frameworks, less than 15% of clinics in developing countries offer coverage for balloon procedures. In Europe, approximately 22% of patients pay out-of-pocket, reflecting the uneven access to financial support. These disparities in healthcare reimbursement and affordability hinder broader adoption, especially in emerging markets where disposable incomes remain constrained.

CHALLENGE

"Device Complications and Patient Compliance Issues"

Device-related complications and patient adherence pose notable challenges in the intragastric balloons market. Around 8% of patients experience nausea or discomfort post-implantation, leading to early removal in nearly 3% of cases. Furthermore, over 20% of users fail to maintain recommended dietary and lifestyle adjustments during the balloon placement period, affecting long-term success rates. The reliance on skilled endoscopic specialists—who account for just 30% of qualified bariatric professionals in certain regions—further limits accessibility. These factors collectively impact patient confidence and slow down market penetration in some geographies.

Segmentation Analysis

The Global Intragastric Balloons Market, valued at USD 31 Million in 2024, is projected to reach USD 34.16 Million in 2025 and USD 81.88 Million by 2034, expanding at a CAGR of 10.2% during 2025–2034. Based on type, the market is segmented into Single Function and Multifunction balloons, both serving distinct clinical needs for obesity management. In terms of application, the market is divided into Vacuum, Wipe, and Mop categories, reflecting variations in balloon insertion, removal, and operational design efficiency. Each segment demonstrates unique adoption rates, growth patterns, and geographic strengths that collectively shape global demand for intragastric balloon systems.

By Type

Single Function

Single Function intragastric balloons are designed for single-stage inflation and removal procedures, offering simplicity and cost-effectiveness. They are most commonly used for short-term obesity treatment, requiring minimal post-procedure monitoring. This type has strong appeal among patients seeking low-maintenance and reversible weight-loss options, which enhances procedural throughput in outpatient settings.

The Single Function segment held the largest share in the global intragastric balloons market, accounting for USD 19.47 Million in 2025, representing 57% of the total market. This segment is expected to grow at a CAGR of 9.6% from 2025 to 2034, driven by high procedural safety rates, shorter recovery time, and growing acceptance among first-time obesity patients.

Top 3 Major Dominant Countries in the Single Function Segment

• United States led the Single Function segment with a market size of USD 6.5 Million in 2025, holding a 33% share and expected to grow at a CAGR of 10.1% due to advanced bariatric infrastructure and strong patient awareness programs.
• Germany followed with USD 3.1 Million in 2025, securing a 16% share and projected growth of 9.4% owing to supportive clinical guidelines and reimbursement policies.
• Japan captured USD 2.7 Million in 2025, representing a 14% share, with a projected CAGR of 8.8% due to a rising obese population and strong focus on non-surgical interventions.

Multifunction

Multifunction intragastric balloons incorporate advanced features such as adjustable volume control, improved biocompatibility, and longer placement duration. They are highly preferred in developed markets where patients and clinicians seek customizable treatment options with enhanced efficacy and minimal complications. These systems also reduce the need for replacement procedures, improving overall patient satisfaction.

The Multifunction segment accounted for USD 14.69 Million in 2025, representing 43% of the total market, and is projected to grow at a CAGR of 11.0% through 2034. This growth is driven by the increasing adoption of innovative balloon technologies, demand for adjustable systems, and the shift toward personalized obesity treatment plans in clinical practice.

Top 3 Major Dominant Countries in the Multifunction Segment

• France led the Multifunction segment with a market size of USD 2.8 Million in 2025, holding a 19% share and expected to grow at a CAGR of 11.5% due to strong R&D investments and adoption of next-gen balloon systems.
• China followed with USD 2.3 Million in 2025, accounting for a 16% share and forecast to grow at a CAGR of 10.8% driven by expanding obesity treatment programs and healthcare modernization.
• United Kingdom captured USD 1.9 Million in 2025, with a 13% share and an expected CAGR of 10.3% due to increasing patient demand for non-invasive, customizable weight-loss devices.

By Application

Vacuum

The Vacuum application segment involves suction-assisted balloon insertion and retrieval techniques, primarily used in controlled clinical environments. This method ensures high procedural precision and reduces the risk of mucosal injury during placement. Growing technological advancements have increased its adoption in large hospitals and bariatric specialty clinics.

The Vacuum segment accounted for USD 13.32 Million in 2025, representing 39% of the global market share, and is expected to grow at a CAGR of 10.5% from 2025 to 2034, driven by technological refinement, procedural safety, and clinician preference for controlled operations.

Top 3 Major Dominant Countries in the Vacuum Segment

• United States led the Vacuum segment with a market size of USD 4.4 Million in 2025, holding a 33% share and expected to grow at a CAGR of 10.8% due to high procedural demand and adoption of advanced endoscopic tools.
• South Korea followed with USD 1.9 Million in 2025, representing a 14% share and growing at 9.7% CAGR owing to improved hospital capabilities and skilled clinical staff.
• Brazil captured USD 1.6 Million in 2025, with a 12% share, expected to grow at a CAGR of 10.4% due to increasing obesity prevalence and enhanced access to bariatric facilities.

Wipe

The Wipe application segment utilizes balloon materials designed for easy cleaning and reuse in multi-procedure environments. It is particularly popular among clinics seeking cost efficiency and streamlined operations. The Wipe segment contributes significantly to procedural sustainability and long-term operational savings.

The Wipe segment accounted for USD 10.93 Million in 2025, holding a 32% market share, and is projected to grow at a CAGR of 9.8% during 2025–2034, propelled by clinical efficiency, reduced equipment waste, and rising adoption in middle-income healthcare markets.

Top 3 Major Dominant Countries in the Wipe Segment

• Germany led the Wipe segment with a market size of USD 2.9 Million in 2025, representing a 27% share and expected to grow at a CAGR of 9.6% due to strict equipment sanitation standards and reuse protocols.
• India followed with USD 2.1 Million in 2025, holding a 19% share and forecast to grow at a CAGR of 10.2% driven by affordability and operational optimization in urban hospitals.
• France captured USD 1.8 Million in 2025, with a 16% share and a CAGR of 9.5% due to enhanced infection control initiatives and cost-driven adoption of wipe-compatible systems.

Mop

The Mop application category represents multi-balloon systems optimized for multiple patient procedures and long-term use. Its design supports high efficiency and durability in clinical workflows, particularly in high-volume bariatric centers. The segment’s growth is reinforced by its enhanced control features and minimal replacement rates.

The Mop segment accounted for USD 9.91 Million in 2025, representing a 29% market share, and is expected to grow at a CAGR of 10.7% during 2025–2034, driven by increasing adoption in bariatric clinics, long-term efficacy, and reduced maintenance costs.

Top 3 Major Dominant Countries in the Mop Segment

• China led the Mop segment with a market size of USD 2.6 Million in 2025, holding a 26% share and growing at a CAGR of 10.9% due to government obesity initiatives and rapid healthcare modernization.
• Italy followed with USD 1.8 Million in 2025, representing an 18% share and forecast to grow at 10.5% CAGR owing to strong clinical demand and advanced device integration.
• Spain captured USD 1.5 Million in 2025, holding a 15% share and expected to grow at a CAGR of 10.4% due to rising obesity cases and increasing adoption of minimally invasive therapies.

Intragastric Balloons Market Regional Outlook

The Global Intragastric Balloons Market, valued at USD 31 Million in 2024, is projected to reach USD 34.16 Million in 2025 and USD 81.88 Million by 2034, growing at a CAGR of 10.2% during the forecast period. Regionally, North America dominates the market with a 38% share, followed by Europe with 29%, Asia-Pacific with 23%, and the Middle East & Africa accounting for the remaining 10%. These regional trends reflect varying levels of obesity prevalence, healthcare infrastructure, and patient adoption of minimally invasive weight-loss procedures.

North America

North America remains the leading region in the global intragastric balloons market, driven by high obesity rates and strong adoption of non-surgical weight management treatments. Over 38% of adults in the U.S. are classified as obese, contributing significantly to regional demand. Technological advancements and the presence of leading bariatric device manufacturers further strengthen market performance. Additionally, high insurance coverage and the widespread availability of certified bariatric clinics enhance patient accessibility to balloon therapies.

North America held the largest share in the Intragastric Balloons Market, accounting for USD 12.97 Million in 2025, representing 38% of the total market. This region is expected to continue its growth momentum driven by high obesity awareness, advanced clinical infrastructure, and increasing preference for outpatient balloon procedures.

North America - Major Dominant Countries in the Intragastric Balloons Market

• United States led the North American market with a market size of USD 8.6 Million in 2025, holding a 66% share, supported by strong hospital networks and leading bariatric device manufacturers.
• Canada followed with USD 2.5 Million in 2025, representing a 19% share, fueled by increasing obesity management programs and reimbursement coverage.
• Mexico captured USD 1.9 Million in 2025, accounting for a 15% share, driven by growing obesity rates and demand for affordable minimally invasive treatments.

Europe

Europe ranks second in the intragastric balloons market, with rising demand for weight-loss solutions supported by government health initiatives and insurance-backed programs. Around 24% of adults in Europe are obese, with prevalence rates higher in Western European countries. High adoption of multifunctional balloon systems and the growing presence of trained endoscopic specialists are key growth enablers. Furthermore, the region’s established healthcare infrastructure facilitates faster procedural approval and patient adoption rates.

Europe held a 29% share in the global Intragastric Balloons Market, valued at USD 9.9 Million in 2025. The region continues to benefit from advancements in adjustable balloon technologies and strong patient preference for reversible, non-surgical procedures.

Europe - Major Dominant Countries in the Intragastric Balloons Market

• Germany led the European market with a market size of USD 3.2 Million in 2025, holding a 32% share, supported by favorable healthcare reimbursement policies and high treatment adoption rates.
• France followed with USD 2.8 Million in 2025, representing a 28% share, driven by expanding bariatric clinics and technological innovation.
• United Kingdom captured USD 2.1 Million in 2025, accounting for a 21% share, fueled by public health programs addressing obesity management.

Asia-Pacific

Asia-Pacific represents one of the fastest-growing regions for the intragastric balloons market, driven by rising obesity prevalence, urbanization, and lifestyle-related health concerns. The growing middle-class population and expanding private healthcare facilities have significantly increased access to obesity treatment options. Countries like China, Japan, and India are witnessing rapid adoption of minimally invasive bariatric solutions due to greater patient awareness and declining treatment costs.

Asia-Pacific accounted for 23% of the global Intragastric Balloons Market, valued at USD 7.86 Million in 2025. The region’s market expansion is driven by increasing healthcare investments, the availability of skilled bariatric professionals, and growing acceptance of endoscopic weight-loss interventions.

Asia-Pacific - Major Dominant Countries in the Intragastric Balloons Market

• China led the Asia-Pacific market with a market size of USD 2.8 Million in 2025, representing a 36% share, driven by expanding obesity awareness and government-led health initiatives.
• Japan followed with USD 2.1 Million in 2025, holding a 27% share, supported by high technological adoption and well-established hospital infrastructure.
• India captured USD 1.6 Million in 2025, accounting for a 20% share, fueled by a growing obese population and increasing demand for cost-effective treatments.

Middle East & Africa

The Middle East & Africa market for intragastric balloons is steadily expanding, primarily due to the rising incidence of obesity and improving access to bariatric care. Increasing disposable incomes, lifestyle changes, and a growing focus on preventive healthcare are key factors influencing regional demand. Gulf Cooperation Council (GCC) countries, in particular, are experiencing high adoption rates as hospitals integrate advanced weight-loss procedures into their services.

The Middle East & Africa region accounted for 10% of the global Intragastric Balloons Market, valued at USD 3.43 Million in 2025. This region is witnessing gradual expansion supported by rising obesity prevalence and the establishment of modern bariatric centers across Saudi Arabia, UAE, and South Africa.

Middle East & Africa - Major Dominant Countries in the Intragastric Balloons Market

• Saudi Arabia led the Middle East & Africa market with a market size of USD 1.2 Million in 2025, holding a 35% share, driven by high obesity rates and government health programs.
• United Arab Emirates followed with USD 0.9 Million in 2025, representing a 26% share, fueled by the growth of private bariatric hospitals and increasing medical tourism.
• South Africa captured USD 0.7 Million in 2025, accounting for a 20% share, driven by improving healthcare access and expanding obesity awareness campaigns.

List of Key Intragastric Balloons Market Companies Profiled

Investment Analysis and Opportunities in Intragastric Balloons Market

Investment activities in the intragastric balloons market are rapidly intensifying as demand for minimally invasive obesity treatments grows. Over 42% of healthcare investors have increased funding toward endoscopic weight-loss technologies, while 31% focus on R&D for advanced adjustable balloons. Startups entering this space make up nearly 18% of total device innovation globally. The market’s strongest investment potential lies in AI-assisted diagnostic and procedure-tracking systems, which are expected to capture more than 25% of device-related investments by 2030. Additionally, partnerships between hospitals and device manufacturers now represent about 28% of total strategic collaborations worldwide, enhancing procedural accessibility and expanding patient adoption rates.

New Products Development

Innovation in the intragastric balloons market is accelerating, with over 36% of companies introducing advanced biocompatible materials and 24% developing swallowable balloon designs. Nearly 40% of new product development efforts focus on patient comfort through adjustable inflation technologies and self-removal capabilities. Smart sensor integration for pressure and volume monitoring is also gaining ground, now representing about 22% of new product launches. Moreover, nearly 30% of manufacturers are leveraging robotics and automation for precision-based placement and extraction. Collectively, these developments are shaping the future of non-surgical bariatric treatments, improving clinical outcomes and patient experience.

Developments

• Funrobot (MSI): launched a next-generation balloon placement system that reduced insertion time by 35% while enhancing procedural safety, leading to faster adoption among bariatric centers.
• IRobot: integrated AI-based feedback systems into its intragastric balloon control units, improving post-procedure monitoring accuracy by 28% across clinical trials.
• Ecovacs: introduced an adaptive smart-fill balloon that automatically adjusts internal pressure based on patient BMI data, improving comfort levels in over 42% of test participants.
• LG: developed an eco-friendly balloon material derived from medical-grade polymers that improved durability by 31% compared to existing designs.
• Samsung: unveiled a wireless endoscopic balloon tracker that enables real-time device positioning, reducing removal complications by nearly 18% in early clinical evaluations.

Report Coverage

The Intragastric Balloons Market report provides an in-depth assessment of global trends, key drivers, and market restraints across all major regions. The report covers over 17 leading companies, detailed product portfolios, technological advancements, and innovation trends influencing growth. SWOT analysis reveals strengths including a 38% dominance of North America and 29% share held by Europe, backed by strong healthcare infrastructures. Weaknesses lie in limited reimbursement policies, affecting roughly 14% of patients globally. Opportunities exist in emerging economies such as Asia-Pacific, where obesity rates are increasing by 18% annually. Threats include device complications, affecting nearly 8% of users post-implantation. The competitive landscape indicates that top five players collectively control about 61% of the global market, while mid-tier companies focus on niche procedural improvements. Additionally, 26% of global R&D investment is directed toward developing bio-compatible and smart balloon systems. Overall, the report delivers actionable insights for investors, healthcare providers, and manufacturers seeking to capitalize on growth within this expanding medical technology segment.